Development of saponin dmlt adjuvant (SDA)
Active Definitive Contract Awarded Last action
- Contract number
- 75N93023C00045
- Awardee
-
The Administrators Of Tulane Educational Fund UEI XNY5ULPU8EN6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,697,750
Award facts
- Opportunity
-
- 75N93022R00009 Solicitation number
- Contract value 100% obligated
- $6,697,749.97 Current and potential, with all options
- Completion date 62% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 24 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- New Orleans, LA 70112, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $2,002,363 | |
| Funding Only Action | -$0 | |
| Other Administrative Action | $1,493,832 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $1,598,870 | |
| Original award | $1,602,685 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $6.7 million firm fixed price definitive contract to The Administrators Of Tulane Educational Fund, doing business as Tulane University, for development of saponin DMLT adjuvant on September 30, 2023, with performance completion by September 29, 2028.
The contract funds preclinical development of combination adjuvants for oral vaccine delivery, spanning saponin adjuvant characterization and purification, dual-potency evaluation methods, and pre-IND regulatory preparation. Work is performed in New Orleans, Louisiana.
Tulane engages three named subcontractors: Q-Vant Biosciences, Inc. provides Type-2 grade saponins and QS-21 adjuvants across development milestones; Path A Washington Nonprofit Corp supports combination adjuvant formulation for oral delivery; and The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. generates recombinant ETEC and Campylobacter jejuni antigens, provides bacterial strains, and delivers hands-on technical training for small animal model development and immunogenicity studies.
Service Contract Inventory data for this contract shows 6.3 FTEs and 13,173 contractor hours invoiced in FY2025, with a blended government-paid hourly rate of $142.48/hr. FY2024 invoiced $1 million across 7.3 FTEs at $67.01/hr, reflecting year-over-year rate escalation.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Q-Vant Biosciences, Inc. | $381,249 | |
| Path | $305,854 | |
| Path | $313,194 | |
| Q-Vant Biosciences, Inc. | $231,969 | |
| The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | $256,034 |
Quick answers
Who was awarded contract 75N93023C00045?
75N93023C00045 was awarded to The Administrators Of Tulane Educational Fund by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2023.
How much is contract 75N93023C00045 worth?
The government has obligated $6,697,750 on 75N93023C00045.
Was contract 75N93023C00045 competed?
The extent of competition for 75N93023C00045 was full and open competition. The government received 24 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award